Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Dose Skipping in mRCC
NCT07077161Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC). Started Jan 2026; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07077161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077161.